Canada To Have Patent Term Extensions Soon – And An Export Waiver

A bill implementing the provisions of the EU-Canada CETA trade deal is expected to be approved soon, bringing a new Certificate of Supplementary Protection together with an export manufacturing waiver, and some changes to the patent litigation system.

Patent Law
Canada's patent laws are to be changed to allow for patent term extensions

Legislation implementing patent term extensions for pharmaceuticals in Canada is expected to come into effect in May or early June this year after completion of the ratification process for the Comprehensive Economic and Trade Agreement (CETA), the trade deal that Canada and the EU signed in October last year, according to Jody Cox, vice-president, federal & international affairs, at the Canadian Generic Pharmaceutical Association.

The new Certificate of Supplementary Protection (CSP) will be similar to the Supplementary Protection Certificate (SPC) that has been available...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Legal & IP

  • ADHD

    This is regarding ADHD.

  • GB-Leadership-Free: Article with 150 words (Time to read is < 1 min)

     
    • By 

    In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.

  • MPP Finds Three More Partners On Key Hepatitis C Treatment

     
    • By 

    The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.

  • Troubled Teligent Enters Bankruptcy Proceedings As CEO Resigns

     
    • By 

    Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.

More from Generics Bulletin